Search alternatives:
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
ms decrease » _ decrease (Expand Search), mean decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 ms » 50 mg (Expand Search), 50 mm (Expand Search)
a non » _ non (Expand Search)
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
ms decrease » _ decrease (Expand Search), mean decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 ms » 50 mg (Expand Search), 50 mm (Expand Search)
a non » _ non (Expand Search)
-
41
-
42
-
43
-
44
-
45
-
46
AMPs are increased in lesional HS, but DCD and other sweat-gland associated proteins are decreased.
Published 2019“…<p>(A) Volcano plot showing increased or decreased genes in HS. …”
-
47
-
48
-
49
-
50
-
51
-
52
-
53
The decrease or inhibition of Hsp90 induced REST degradation.
Published 2019“…(D) The level of REST dramatically reduced in differentiated SH-SY5Y cells treated with GA (1 μM) or PU-H71 (50 nM) at 24 h. (E) The REST level decreased by GA more than 50% and (F) PU-H71 more than 80%, respectively. …”
-
54
Juvenile demyelination leads to a substantial decrease in potassium currents in PV interneurons of the PFC.
Published 2025“…Scale: 500 pA, 100 ms. <b>B</b>. I–V curves showing a significant decrease in Kv amplitude in PV interneurons from mice that underwent juvenile demyelination. …”
-
55
-
56
-
57
-
58
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
Published 2025“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
-
59
-
60